

PROGRAMME

PROGRAMME:

08:15 URSULA SCHMIDT-ERFURTH MD

Welcome

**SESSION 1:
EPIDEMIOLOGY / VASCULAR BIOLOGY**

Chair: Ronald Klein MD, Ingrid Pabinger MD

08:30 Ronald Klein MD

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

Epidemiology of retinal vein occlusion

09:00 Tom Williamson MD

St. Thomas Hospital, London, UK

Haemodynamic particularities of retinal blood vessels: the "throttle" mechanism and arterial shear stress in the retinal vein

09:30 Charles Esmon PhD

Howard Hughes Medical Institute and the Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

Bringing ophthalmology and thrombosis together

10:00 Jean-Luc Wautier MD PhD

University Diderot Paris and Institut National de la Transfusion Sanguine, Paris, France

Red blood cells in vascular disease - Red cells: the culprit of retinal vein occlusion?

10:30 Coffee break

**SESSION 2:
SELECTED RISK FACTORS/ POTENTIAL RELEVANCE**

Chair: Thaddeus Dryja MD, Charles Esmon PhD

11:00 Philip G. de Groot MD

University Medical Center, Department of Clinical Chemistry and Haematology, Utrecht, The Netherlands

The antiphospholipid syndrome

11:30 Steven R. Lentz MD PhD

University of Iowa, Iowa City, Iowa, USA

Mechanism of homocysteine-induced atherothrombosis

12:00 Thaddeus Dryja MD

*Translational Medicine in Ophthalmology and Molecular Genetics,
Novartis Institutes of Biomedical Research
Cambridge, Massachusetts, USA*

Molecular genetics of retinal vascular diseases

12:30 Lunch

PROGRAMME

SESSION 3:

CURRENT TREATMENT OPTIONS:

HAEMATOLOGY, VASCULAR ENDOTHELIAL GROWTH FACTOR AND STEROIDS

Chair: Ursula Schmidt-Erfurth MD, Mark Blumenkranz MD

13:30 Ingrid Pabinger MD

Department of Internal Medicine, Medical University Vienna, Austria

Retinal vascular disease: Therapeutic approaches from a haematological point of view

14:00 Jeffrey S. Heier MD

Tufts University School of Medicine, Medford, Massachusetts, USA and Harvard Medical School, Boston, Massachusetts, USA

Anti-VEGF Therapy in the Treatment of Retinal Venous Occlusive Disease

14:30 Baruch D. Kuppermann MD PhD

Department of Ophthalmology, University of California, Irvine, California, USA

The role of intravitreal steroids and implants in the management of retinal vein occlusions

15:00 Mark S. Blumenkranz MD

Stanford University, California, USA

RAPAMYCIN (Sirolimus) The use of mTOR inhibition is a treatment for retinal vascular disease associated with proliferation and hyperpermeability

15:30 Coffee break

SESSION 4:

CURRENT TREATMENT OPTIONS:

LASER, SURGERY

Chair: Baruch D. Kuppermann MD PhD, Jeffrey S. Heier MD

16:00 Daniel Finkelstein MD

The Wilmer Ophthalmological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA

The role of Laser Treatment in Retinal Vein Occlusion

16:30 Jose Garcia-Arumi MD

Institut de Recerca Hospital Universitari Vall D'Hebron, Barcelona, Spain

Retinal vascular occlusion: the surgical approach

SESSION 5:

PANEL DISCUSSION

17:00 – 18:00